What is the chemical formula of semaglutide?

Why does semaglutide have such a large and unusual chemical formula?

Most medicines you pick up at a pharmacy are small organic molecules, aspirin, for instance, is C₉H₈O₄. Semaglutide sits in a completely different category. Its formula, C₁₈₇H₂₉₁N₄₅O₅₉, reflects a chain of 34 amino acids built to resemble the body's own GLP-1 hormone, which is released from the gut after eating and tells the brain you have had enough food.

The human GLP-1 molecule degrades rapidly, its half-life in the body is measured in minutes. Semaglutide was designed to outlast it dramatically. Scientists at Novo Nordisk introduced three key structural changes: they swapped the amino acid at position 8 to resist the enzyme that normally dismantles GLP-1; they replaced one amino acid at position 34 to remove a site where another enzyme attacks; and, most significantly, they attached a long fatty-acid chain to the lysine residue at position 26. That chain tethers the molecule loosely to albumin, a protein that circulates in the blood, dramatically slowing the kidney's ability to filter semaglutide out. The result is a half-life of roughly seven days, which is why one subcutaneous injection covers a full week.

If you want to explore how these structural decisions compare with other approaches, the detailed breakdown of semaglutide's chemical structure covers the three modifications side by side.

Does the chemical formula explain why semaglutide causes nausea?

To a meaningful extent, yes. Because semaglutide mimics GLP-1, it activates GLP-1 receptors not only in the hypothalamus (where appetite signalling happens) but also in the gut wall, where it slows gastric emptying. Food moves through the stomach more slowly, which prolongs the sensation of fullness, but it also means the stomach is fuller for longer, and nausea is the common consequence, particularly when treatment begins or a dose increases.

The NHS patient information for semaglutide lists nausea, vomiting, diarrhoea, constipation, indigestion and burping among the more frequently reported effects. Fatigue and headache also feature. For most people these effects are most noticeable in the first couple of weeks at each dose level and settle as the body adjusts. They are a direct pharmacological consequence of the molecule's mechanism, not a sign that something has gone wrong.

One practical habit worth building: before each new pen is used, glance at the liquid inside the viewing window. It should be clear and colourless. If it looks cloudy, discoloured or contains particles, do not use it, contact the pharmacy. It takes under a minute and confirms the pen is in good condition.

For a fuller account of what the clinical evidence says about tolerability, the semaglutide overview covers the trial profile in detail alongside the licensed UK products.

Is the formula the same in Wegovy, Ozempic and oral semaglutide tablets?

The semaglutide molecule itself is identical across all approved products. What differs is the dose, the route of administration and what the medicine is licensed for. Wegovy (injection) is licensed by the MHRA for weight management; Ozempic is the same molecule at lower doses, licensed for type 2 diabetes and not for weight loss. Oral semaglutide tablets (Wegovy tablets, approved by the MHRA on 11 June 2026 as the first oral GLP-1 medicine licensed for weight management in the UK) achieve absorption by co-formulating semaglutide with an absorption enhancer called SNAC, which temporarily alters the stomach lining locally to allow the peptide to pass into the bloodstream before enzymes in the gut can break it down.

The oral route makes the dosing schedule different: tablets start at 1.5 mg daily and escalate over several months to the 25 mg maintenance dose. The injection version starts at 0.25 mg weekly. Both are semaglutide; neither is appropriate to take without a prescriber's oversight, and neither should be compared purely on dose numbers because the delivery mechanism changes absorption significantly. For detail on how the formulation affects what the tablet contains, the page on how Wegovy is formulated goes into the excipients and why the tablet must be taken on an empty stomach with only a small amount of plain water.

You can also read more about how semaglutide's chemistry as a GLP-1 analogue underpins both injection and tablet formulations.

Does knowing the formula matter when choosing a provider?

Not directly, but the question behind the question often does matter. People who research the chemical formula of semaglutide are frequently trying to establish whether a product they have been offered is genuine. That is a legitimate concern. The MHRA has warned repeatedly about counterfeit weight-loss pens sold online, some of which have been found to contain insulin or other substances rather than semaglutide. The formula itself cannot be verified by the patient, but the legitimacy of the supply chain can be checked.

Any online pharmacy dispensing Wegovy in the UK must be registered with the GPhC. You can check a pharmacy's registration on the GPhC register in seconds. Red flags include sellers offering semaglutide without a prescription, prices that sit well below the market range, and discount codes attached to injectable medicines, none of which are features of a legitimate regulated service.

At nume, every prescription is reviewed personally by a GPhC-registered Independent Prescriber, and medicines are sourced through the licensed UK supply chain. If you are weighing up whether Wegovy might be clinically suitable for you, the free consultation page explains how our review works and what the process involves. There are no obligations, and the clinical assessment happens the same day.

For background on the broader research landscape, including how semaglutide compares with other molecules studied in obesity medicine, the page on semaglutide as a research compound is worth reading alongside this one. You can also explore the Wegovy treatment page for a practical overview of the injection as licensed in the UK, or visit our weight-loss treatments overview to see how it sits alongside other options we prescribe.